📣Excited to share with the #nephrology community the latest updates in #C3G and primary #ICMPGN clinical trials at #ERA25. If you are a healthcare professional, do not miss the late breaking session: Innovative Kidney Trials at ⏲️15:00 at the Square #nephrology #kidneydisease
We are excited to be at #ERA25 in sunny Vienna🔅. If you are a healthcare professional join us at booth X3.110 to meet the #Sobi team and learn more about #C3G #IC-MPGN #complement #Rare_Sobi #Sobi_nephrology
📣 Save the date! Our symposium at #ERA25, where we will explore the power of #complement inhibition in #C3G and primary #ICMPGN, join Prof Marina Vivarelli, Prof. Matthew Pickering and Prof. Fadi Fakhouri on 🗓️ June 6, 🕙 10:00-11:00 (CEST) in Hall B
Findings on the Sparsentan study: A New Dawn for IgA Nephropathy.
⬇️ Download the visual abstract: www.theisn.org/wp-co...
📽️ Watch the industry webinar: academy.theisn.org/p...
Supported by @travererare.bsky.social
@kidneydoc101.bsky.social is the President Elect of the @theisn.org ! Honoured to call this exceptional woman and Leader my friend and colleague, and look forward to her vibrant contributions to #Kidneyhealth
Sparsentan for FSGS isn’t dead yet… ir.travere.com/news-release...
Join the @theisn.org ! 🌍
We continue our mission in advancing kidney care! The SoMe team is enjoying the #ISNWCN #MedSky #NephSky
The 2024 USRDS report is out (a few weeks ago actually)
usrds-adr.niddk.nih.gov/2024
It’s a treasure trove of data for nephrology nerds, aka all of #NephSky
So, short 🧶 on ESRD incidence/prevalence
Fascinating - didn’t learn this at medical school!
This is so very helpful - thanks for putting it all together
The phase 3 VALIANT trial has been evaluating the drug, pegcetacoplan, in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). pmlive.com/pharma_news/... #kidneyhealth
🫘🧬Complement testing in patients with C3 Glomerulopathy
doi.org/10.1093/ndt/...
@ndt journal
